|
Tracer
|
Injected activity, MBq/rat
|
Injected dose, nmol/kg
|
Rats per treatment group (saline/raclopride)
|
Pre-treatment time interval, min
|
|---|
|
[18F]FEt-AMC13
|
9.4 ± 1.2
|
0.55 ± 0.14
|
4/4
|
47 ± 27
|
|
[18F]FBu-AMC13
|
20.8 ± 10.6
|
0.45 ± 0.26, 10.4, 11.0a
|
3/3
|
52 ± 19
|
|
[18F]FEt-AMC15
|
26.6 ± 15.2
|
1.06 ± 0.65
|
3/3
|
48 ± 10
|
|
[11C]raclopride
|
16.9 ± 5.3
|
1.26 ± 0.16
|
4 (saline only)
|
36 ± 3
|
- One rat in the saline-treated group and one rat in the raclopride-treated group were injected, respectively, with 10.4 and 11.0 nmol/kg tracer. As all outcome measures (time-activity curves, uptake ratios) obtained from these animals were very close to the results from other animals in the corresponding groups, these results were not omitted or separated, but combined with the rest of the data
